SPY367.44+0.65 0.18%
DIA300.87+1.69 0.56%
IXIC12,413.39+64.02 0.52%

Wells Fargo Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $60

Wells Fargo maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $39 to $60.

· 11/16/2020 11:54
Wells Fargo maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $39 to $60.